Pipeline

We build a world-class pipeline by proprietary discovery platforms. Our innovation engine has been validated by clinical assets and global partnerships.

Get in Touch →

You are here: Home » Pipeline » PHASE 1

PHASE 1

BSI-502

Target / Modality: TSLP x IL4R
Indication: AD/SA
Status: AD-Phase 1
Partner(territory right): Aclaris (Global ex-China)

PHASE 1

BSI-060T

Target / Modality: Anti-Siglec-15 mAb
Indication: Oncology
Status: Phase 1
Partner(territory right): Pyxis Oncology (Global ex-China)

PHASE 1

BSI-585

Target / Modality: PD-1 x ILT4 bispecific
Indication: Oncology
Status: Phase 1
Partner(territory right): Celldex（Global ex-China)

PHASE 1

BSI-128

Target / Modality: HER2 (Novel Epitope)
Indication: Solid Tumors
Status: Phase 1
Partner(territory right): AnkeBio (China)

PHASE 1

BSI-082

Target / Modality: SIRPα mAb
Indication: Solid Tumors
Status: Phase 1 (IIT)
Partner(territory right): Available for partnerhip

Find us in China, Hong Kong SAR, the United States & Australia

Quick Links